Viridian Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $75 | $72 | $72 | $86 |
Gross Profit | 75 | 72 | -51 | 86 |
EBITDA | -100,108 | -86,209 | -78,744 | -75,555 |
EBIT | -100,221 | -86,326 | -78,867 | -75,685 |
Net Income | -100,735 | -86,912 | -79,725 | -76,689 |
Net Change In Cash | 75 | 72 | 72 | 86 |
Free Cash Flow | -75,415 | -92,739 | -73,446 | -67,999 |
Cash | 117,324 | 116,215 | 99,594 | 200,317 |
Basic Shares | 81,593 | 81,344 | 80,052 | 66,420 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $302 | $314 | $1,772 | $2,963 |
Gross Profit | 302 | -1,008 | 1,017 | 2,343 |
EBITDA | -265,663 | -234,565 | -128,633 | -78,790 |
EBIT | -266,903 | -235,087 | -129,388 | -79,410 |
Net Income | -269,949 | -237,734 | -125,444 | -79,416 |
Net Change In Cash | 302 | 314 | 1,772 | 2,963 |
Cost of Revenue | 113,280 | -3,598 | ||
Free Cash Flow | -232,830 | -185,068 | -94,635 | -54,919 |
Cash | 99,594 | 102,827 | 155,579 | 42,299 |
Basic Shares | 67,886 | 44,755 | 32,087 | 11,918 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$1 |
2025-03-31 | -$0.86 |
2024-12-31 | -$0.81 |
